Biocon share price may react as USFDA clears cancer biosimilar Jobevne for US market
Biocon shares are likely to be in focus on April 11 after its subsidiary, Biocon Biologics, received USFDA approval for its cancer treatment drug Jobevne. The medicine is a biosimilar version of Bevacizumab, which is used in cancer therapy. This is seen as a positive step for the company’s business in the US market. Jobevne […]
Biocon share price may react as USFDA clears cancer biosimilar Jobevne for US market Read More »